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Abstract
Background: Photoimmunotherapy (PIT) is a novel type of molecular optical imaging-guided cancer phototherapy
based on a monoclonal antibody conjugated to a photosensitizer, IR700, in combination with near-infrared (NIR)
light. PIT rapidly causes target-specific cell death by inducing cell membrane damages and appears to be highly
effective; however, we have previously demonstrated that tumor recurrences were eventually seen in PIT-treated mice,
likely owing to inhomogeneous mAb-IR700 conjugate distribution in the tumor, thus limiting the effectiveness of PIT as
a monotherapy. Here, we examined the effects of human epidermal growth factor-2 (HER2)-targeted PIT in combination
with 5-fluorouracil (5-FU) compared to PIT alone for HER2-expressing human gastric cancer cells.
Methods: NCI-N87 cells, HER2-positive human gastric cancer cells, were used for the experiments. Trastuzumab, a
monoclonal antibody directed against HER2, was conjugated to IR700. To assess the short-term cytotoxicity and examine
the apoptotic effects upon addition of 5-FU in vitro, we performed LIVE/DEAD and caspase-3 activity assays. Additionally,
to explore the effects on long-term growth inhibition, trypan blue dye exclusion assay was performed. NCI-N87 tumor
xenograft models were prepared for in vivo treatment studies and the tumor-bearing mice were randomized into various
treatment groups.
Results: Compared to PIT alone, the combination of HER2-targeted PIT and 5-FU rapidly induced significant cytotoxicity
in both the short-term and long-term cytotoxicity assays. While both 5-FU and/or trastuzumab-IR700 conjugate treatment
induced an increase in caspase-3 activity, there was no additional increase in caspase-3 activity upon NIR light irradiation
after incubation with 5-FU and/or trastuzumab-IR700. The combination of HER2-targeted PIT and 5-FU resulted in greater
and longer tumor growth inhibition than PIT monotherapy in vivo. This combined effect of PIT and 5-FU is likely owing
to their different mechanisms of inducing tumor cell death, namely necrotic membrane damage by PIT and apoptotic
cell death by 5-FU and trastuzumab.
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Conclusions: PIT in combination with 5-FU resulted in enhanced antitumor effects compared to PIT alone for
HER2-expressing human gastric cancer in vitro and in vivo. This combination photoimmunochemotherapy
represents a practical method for treating human gastric cancer and should be investigated further in the
clinical setting.
Keywords: Molecular targeted therapy, Photoimmunotherapy, HER2, Gastric cancer, 5-fluorouracil
Background
Gastric cancer is the fourth most commonly diagnosed
cancer and the second leading cause of cancer-related
death worldwide. Moreover, gastric cancer is associated
with a poor prognosis [1–3]. Conventional cancer ther-
apies, such as surgery, radiation, and chemotherapy, can
cause damage or toxicity to both the adjacent and dis-
tant normal tissues, which in turn limits the effective-
ness of these therapies [4, 5]. To achieve more effective
cancer control, as well as to minimize the side effects as-
sociated with conventional cancer therapies, molecular
targeted cancer therapies, such as monoclonal antibodies
and tyrosine kinase inhibitors, have been developed in
recent years [4, 6].
Overexpression of human epidermal growth factor
receptor 2 (HER2), a member of the epidermal
growth factor receptor family, which is known to play
roles in cell proliferation, differentiation, and apop-
tosis [7, 8], has been previously reported in gastric
cancer, as well as in various other cancers [9, 10]. Ac-
cordingly, trastuzumab, a humanized mAb directed
against HER2, has been demonstrated to induce anti-
tumor effects in HER2-positive gastric cancer, both
alone and in combination with various chemothera-
peutic agents [9, 11].
Photoimmunotherapy (PIT) is a newly described can-
cer theranostic system based on a molecular-targeted
mAb conjugated to a photosensitizer, IRDye700DX
(IR700), together with irradiation of near-infrared (NIR)
light (peak at 689 nm) [12]. When exposed to NIR light,
the mAb-IR700 conjugate is activated; however, it only
shows selective activity against cells to which the conju-
gate is specifically bound and fluorescent, whereas it has
no effect on the cells that do not express that particular
molecular target [12–14]. NIR light exposure with mAb-
IR700 conjugate leads to rapid and target-selective cell
death, mainly as a result of necrosis, in vitro [12], and
tumor shrinkage can be obtained even with a single ad-
ministration of mAb-IR700 followed by a single expos-
ure to NIR light in vivo [12–14]. However, although PIT
has been demonstrated to be highly effective, our previ-
ous study showed that a subset of cancer cells survived
after PIT in an in vivo mouse model, and tumor recur-
rences were eventually seen in the treated mice as a re-
sult of inhomogeneous mAb-IR700 distribution in the
targeted tumor [15]. Moreover, tumor heterogeneity is
relatively common in human epithelial carcinomas, in-
cluding in gastric cancer [9, 16, 17], and this may limit
the effects of PIT treatment.
Here, we investigated whether the antitumor effect of
combined HER2-targeted PIT with conventional chemo-
therapy was enhanced compared to treatment with PIT




Trastuzumab (Herceptin®), a mAb directs against the
extracellular domain of HER2, was purchased from Chugai
Pharmaceutical Co., Ltd. (Tokyo, Japan). IRDye700DX N-
hydroxysuccinimide ester (IR700; a photosensitizer) was
purchased from LI-COR Biosciences (Lincoln, NE). The
chemotherapeutic agent 5-fluorouracil (5-FU), which is
widely used as a standard treatment for human gastric can-
cer [18], was purchased from Kyowa Hakko Kirin Co., Ltd.
(Tokyo, Japan).
Synthesis and purification of IR700-conjugated
trastuzumab
Trastuzumab (1.0 mg, 6.8 nmol) was incubated with
IR700 (66.8 μg, 34.2 nmol) in 0.1 M Na2HPO4 (pH 8.5)
at room temperature for 1 h. The mixture was purified
using a Sephadex G50 column (PD-10; GE Healthcare,
Wauwatosa, WI). The concentrations of IR700 and pro-
tein were measured by absorption reading using spec-
troscopy (UV-1800; Shimadzu corp., Kyoto, Japan) to
confirm the number of fluorophore molecules conju-
gated to each trastuzumab molecule. The number of
IR700 molecules per trastuzumab molecule was adjusted
to approximately 3.
Cell lines and culture conditions
Two human gastric cancer cell lines were used in this
study. HER2-expressing NCI-N87 cells were purchased
from American Type Culture Collection (Manassas, VA),
and HER2-negative MKN-45 cells were purchased from
RIKEN Cell Bank (Tsukuba, Japan). Both cell lines were
cultured in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10 fetal bovine serum and 1 %
penicillin-streptomycin (Life technologies, Gaithersburg,
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MD) in a humidified incubator at 37 °C in an atmosphere
of 95 air and 5 % carbon dioxide (CO2). The study was car-
ried out in accordance with the Helsinki declaration.
Cytotoxicity assay for human gastric cancer cells by 5-
fluorouracil
To determine the 50 % inhibitory concentration (IC50)
of 5-FU for NCI-N87 and MKN-45 cells, we performed
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The
cells were seeded at 1 × 104 cells per well in a 96-well mi-
croplate, and exposed to various concentrations of 5-FU (0,
0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000 μΜ) for 48 h at
37 °C in 5 % CO2. After the treatments, CellTiter 96® Aque-
ous One Solution (Promega, Madison, WI) was added to
each well, followed by incubation for 2 h at 37 °C in 5 %
CO2, and the absorbance of each well was measured using a
microplate reader (iMark, Bio-Rad, Hercules, CA) at
540 nm.
Determination of HER2 expression for human gastric cancer
cells in vitro
To examine the HER2 expression in NCI-N87 and MKN-
45 cells, IR700 fluorescence was analyzed by flow cytometry
(MACSQant analyzer; Miltenyi Biotec, Bergisch Gladbach,
Germany), and the mean fluorescence intensities were eval-
uated. The cells were seeded in 35-mm dishes at 5 × 105
cells/dish and cultured for 48 h at 37 °C in 5 % CO2. After
3 h incubation with 10 μg/ml of trastuzumab-IR700 conju-
gate (Tra-IR700), the media were removed and the plates
were washed with phosphate-buffered saline (PBS); subse-
quently, flow cytometric analysis was performed. In
addition, to confirm the target specificity, unconjugated
trastuzumab (100 μg/ml) was added to the cells to block
the HER2 molecules before incubation with the Tra-IR700
conjugate. The mean fluorescence intensities were calcu-
lated and compared to the isotype control. Furthermore,
fluorescence microscopy was performed using an IX73
fluorescence microscope (Olympus, Tokyo, Japan) to deter-
mine the HER2-specific binding of Tra-IR700 and the sub-
cellular localization of IR700.
Cytotoxicity assay in response to NIR light irradiation and
5-fluorouracil in vitro
To assess the early stage of cytotoxicity in response to
PIT and 5-FU treatment, we used the LIVE/DEAD® Fix-
able Green Dead Cell Stain Kit (Life Technologies),
which can detect damaged cellular membranes by flow
cytometric analysis. NCI-N87 and MKN-45 cells were
seeded in 35-mm dishes at 5 × 105 cells/dish and cul-
tured for 48 h at 37 °C in 5 % CO2. The following treat-
ment groups were analyzed: (1) PBS without NIR light
irradiation (negative control), (2) IC50 of 5-FU without
NIR light irradiation, (3) 10 μg/ml of Tra-IR700 without
NIR light irradiation, (4) IC50 of 5-FU and 10 μg/ml of
Tra-IR700 without NIR light irradiation, (5) 10 μg/ml of
Tra-IR700, followed by NIR light irradiation, and (6)
IC50 of 5-FU and 10 μg/ml of Tra-IR700, followed by
NIR light irradiation. After 24 h incubation with 5-FU
and/or Tra-IR700, the medium was removed and re-
placed by phenol red-free RPMI 1640 after washing with
PBS. Subsequently, NIR light (1 J/cm2, 2 J/cm2, or 4 J/cm2)
was irradiated to the cells. After the treatments, the cells
were collected in PBS, and LIVE/DEAD green fluorescent
reactive dye was added to the cell suspension. After 30 min
incubation at room temperature, the cells were analyzed by
flow cytometry.
To further explore the long-term growth inhibition,
we performed trypan blue dye exclusion assay. The cells
were seeded at 2 × 105 cells in 35-mm dishes and cul-
tured for 24 h at 37 °C in 5 % CO2. The IC50 of 5-FU
and/or 10 μg/ml of Tra-IR700 were added to the
medium and incubated for another 24 h. Subsequently,
the medium was removed and replaced by phenol red-
free RPMI 1640 after washing with PBS, and NIR light
was irradiated to the cells. At the indicated time point
after NIR light irradiation, the cells were collected, and
the viable cells were counted based on the trypan blue
dye uptake.
Caspase-3 activity assay
To examine the apoptotic effects in response to each in-
dividual treatment or combination thereof, we measured
the activity of caspase-3 using the Caspase-3 colorimet-
ric assay kit (MBL, Nagoya, Japan). The cells were
treated using the same protocol as for the LIVE/DEAD
assay. After the treatments, the cells were washed with
PBS and lysed in cell lysis buffer for 10 min on ice, after
which the cell lysates were centrifuged at 10,000 g for
5 min and the protein concentrations of the superna-
tants were estimated using the bicinchoninic acid (BCA)
protein assay kit (Thermo Fisher Scientific, Waltham,
MA). Equal amounts of protein extracts were incubated
overnight with a reaction buffer containing dithiothreitol
and caspase-3 substrates in a 96-well microplate at 37 °C.
The absorbance at 405 nm was measured using a micro-
plate reader.
HER2-specific accumulation of Tra-IR700 in vivo
Female 6-week-old BALB/c-nu/nu mice (CAnN.Cg-
Foxn1 < nu>/CrlCrlj nu/nu) were obtained from Charles
River Laboratories Japan, Inc. (Yokohama, Japan). All
mice were allowed to acclimatize and recover from
shipping-related stress for 1 week before the study, and
were kept in a controlled light–dark cycle (12 h-12 h)
environment. All animal experiments were conducted in
accordance with the guidelines established by the
Animal Care Committee of the Jikei University School
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of Medicine. To examine Tra-IR700 distribution in vivo,
we prepared tumor xenograft models bearing NCI-N87
and MKN-45 tumors. A total of 5 × 106 NCI-N87 cells
were injected subcutaneously into the right dorsum of
each mouse, and 3 × 106 MKN-45 cells were injected
subcutaneously into the left dorsum of the same mouse.
The tumor xenografts were measured with a caliper, and
the tumor volume was calculated using the following
formula: length × width × height × 0.5 [19]. When each
tumor reached approximately 15 mm3, 50 μg of Tra-
IR700 was injected intravenously. Distribution of IR700
fluorescence was evaluated using the IVIS® Imaging Sys-
tem (Caliper Life Sciences, Hopkinton, MA). Fluores-
cence images were obtained 1, 2, 3, and 5 days after Tra-
IR700 injection under the same settings (e.g. exposure
time, camera binning, and stage height) using isoflurane
anesthesia. All fluorescence images were analyzed with
Image J software (http://rsb.info.nih.gov/ij/; National In-
stitutes of Health, Rockville, MD). The region of interest
was manually determined on each tumor area depending
on where the IR700 fluorescence was localized. The
background regions, each being approximately the same
region size as that of the tumor regions, were subtracted
from the tumor regions in the same mouse.
HER2 targeting photoimmunochemotherapy with Tra-IR700
and 5-FU in vivo
To determine the antitumor effects of PIT in combin-
ation with 5-FU compared to PIT alone in vivo, the fol-
lowing experiments were conducted. A total of 5 × 106
NCI-N87 cells were injected subcutaneously into the
right dorsum of the mice, and the tumor xenografts
were measured with a caliper 3 times per a week, as de-
scribed above. Tumors reaching approximately 15 mm3
in volume were selected and randomized into the follow-
ing 8 groups (at least n = 10 mice in each group): (a) no
treatment, (b) 30 μg/g/day of 5-FU i.p. without NIR light
irradiation, (c) 300 μg of Tra-IR700 i.v. without NIR
light irradiation, (d) NIR light irradiation (100 J/cm2)
without 5-FU or Tra-IR700 injection, (e) 30 μg/g/day of
5-FU i.p. and 300 μg of Tra-IR700 i.v. without NIR light
irradiation, (f ) 30 μg/g/day of 5-FU i.p. followed by NIR
light irradiation (100 J/cm2), (g) 300 μg of Tra-IR700 i.v.
followed by NIR light irradiation (100 J/cm2), and (h)
30 μg/g/day of 5-FU i.p. and 300 μg of Tra-IR700 i.v.
followed by NIR light irradiation (100 J/cm2). Tra-IR700
injection was performed at the time of mouse
randomization (Day 0), and NIR light irradiation was
performed for Tra-IR700 localizing tumors detected by
the in vivo imaging system 24 h after injection (Day 1).
Subsequently, 5-FU was injected on 3 consecutive days
(Day 1 [just after NIR light irradiation], Day 2 and Day
3; total amount: 90 μg/g) (Fig. 4a). All treatments were
performed using isoflurane anesthesia. After the
treatments, the tumor xenografts continued to be mea-
sured 3 times a week and the mice were monitored for
30 days.
Histological analysis
To evaluate the histological changes after the treat-
ments, the mice were euthanized at the indicated time
points and the NCI-N87 tumors were harvested and
fixed in 10 % formalin for 24 h. Serial 10-μm slice
sections were stained with hematoxylin and eosin.
Statistical analysis
Data are expressed as means ± SEM from a minimum of
three experiments. Statistical analyses were carried out
using GraphPad Prism software (GraphPad Software
Inc., La Jolla, CA). For in vitro experiments, Student’s t
test was used to compare the two treatment groups. For
in vivo experiments, the Mann–Whitney U test was used
to evaluate the differences in tumor volume. P < 0.05
was considered to indicate a statistically significant
difference.
Results
HER2 expression of human gastric cancer cells
In vitro HER2 expression was determined by flow cyto-
metric analysis and fluorescence microscopy. In NCI-
N87 and MKN-45 cells, the ratios of the mean fluores-
cence intensity (MFI) compared to the isotype control
were 154.7 ± 15.4 and 3.7 ± 0.4, respectively (n = 3 each)
(Fig. 1a, b). When pre-incubated with 100 μg of uncon-
jugated trastuzumab to block the HER2 molecules, the
signal from Tra-IR700 was completely blocked in both
the NCI-N87 and MKN-45 cells (Fig. 1a, b); the ratios of
the MFI compared to the isotype control in the NCI-
N87 and MKN-45 cells were 7.4 ± 2.7 and 1.9 ± 0.3, re-
spectively (n = 3 each). As only very weak HER2 expres-
sion was found in the MKN-45 cells, we considered
MKN-45 cells as a HER2-negative control in this study.
Fluorescence images were obtained to confirm HER2-
specific IR700 localization during the irradiation of NIR
light. IR700 fluorescence was detected on the surface
and cytoplasmic vesicles in HER2-expressing NCI-N87
cells after 3 h incubation with Tra-IR700, while MKN-45
cells did not show detectable IR700 fluorescence under
the same image acquisition conditions (Fig. 1c, e). While
excitation light irradiation (692 ± 20 nm, power density;
24 mW/cm2) to NCI-N87 cells rapidly induced cellular
swelling and surface bleb formation (Fig. 1c), immediate
cell death was not induced when the cells were pre-
incubated with excess unconjugated trastuzumab
(Fig. 1d). On the other hand, the HER2-negative MKN-
45 cells did not show any morphological changes upon
NIR light irradiation (Fig. 1e).
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In vitro photoimmunochemotherapy for human gastric
cancer cells
We initially determined the cytotoxic effect of 5-FU
for each gastric cancer cell line using the MTS assay.
The IC50 of 5-FU was found to be 3.3 ± 1.5 μM in
NCI-N87 cells and 3.1 ± 0.5 μΜ in MKN-45 cells (n = 3
each). We used the IC50 of 5-FU as the therapeutic dose
for the cells. Previous studies have shown that tumor cell
death in response to PIT is rapidly induced through mem-
branous damage, as determined by the LIVE/DEAD assay
[12–14]. Accordingly, we here employed the same assay to
assess the cytotoxic effects of combination treatment with
PIT and 5-FU. We observed significant differences in the
percentages of cell death between 5-FU alone and un-
treated controls in both NCI-N87 (P = 0.0336) (Fig. 2a)
and MKN-45 cells (P = 0.0013) (Fig. 2b). Moreover, we ob-
served significant cytotoxicity associated with exposure to
Tra-IR700 without NIR light compared to the untreated
controls in NCI-N87 cells (P = 0.0088), but not in MKN-
45 cells. In NCI-N87 cells, the percentage of cell death in
response to PIT was significantly increased compared to
the untreated control in an irradiation dose-dependent
manner (P < 0.001 for all irradiated doses), while no cyto-
toxicity associated with PIT was seen in MKN-45 cells. In
addition, the percentage of cell death in the cells treated
with PIT in combination with 5-FU compared to the cells
treated with PIT alone was significantly increased at all of
the irradiated NIR light doses in NCI-N87 cells (PIT 1 J/
cm2 + 5-FU vs. PIT 1 J/cm2: P = 0.0478; PIT 2 J/cm2 + 5-
FU vs. PIT 2 J/cm2: P = 0.0175; and PIT 4 J/cm2 + 5-FU vs.
PIT 4 J/cm2: P = 0.0113; Fig. 2a), while no combined effect
was observed in MKN-45 cells (Fig. 2b). We also deter-
mined the long-term treatment effects of PIT and 5-FU
using the trypan blue dye exclusion assay. As shown in
Fig. 2c, significant growth inhibition was observed in the
cells treated with PIT in combination with 5-FU com-
pared to PIT alone (4 days after NIR light irradiation: P <
0.001). To determine the mechanism of the cytotoxicity
induced by PIT and/or 5-FU treatment, we next examined
the apoptotic effects of these treatments using the
caspase-3 activity assay in NCI-N87 cells. While a signifi-
cant increase in caspase-3 activity was found when the
cells were treated with 5-FU or Tra-IR700 (without NIR
light), NIR light irradiation did not further increase the
caspase-3 activity (Fig. 2d).
HER2-specific accumulation of trastuzumab-IR700 conjugate
in vivo
We next examined the biodistribution of Tra-IR700 in
the tumor xenograft models by using an in vivo
Fig. 1 In vitro human epidermal growth factor receptor 2 (HER2) expression in human gastric cancer cells. a, b Flow cytometry revealed strong
HER2-specific signals in NCI-N87 cells and very weak signals in MKN-45 cells. Specific binding of trastuzumab-IR700 was demonstrated by excess
trastuzumab blocking. c, d, e Fluorescence microscopy showed HER2-specific IR700 localization in NCI-N87 cells. Conversely, IR700 fluorescence
was not detected in MKN-45 cells or in NCI-N87 cells pre-treated with an excess volume of trastuzumab. Cellular swelling and bleb formation
were rapidly induced after excitation light in NCI-N87 cells but not in MKN-45 cells (lower right). Scale bar, 50 μm. DIC: differential interference
contrast, NIR: near-infrared
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fluorescence imaging system. The NCI-N87 tumors were
specifically visualized with IR700 fluorescence on Day 1
after intravenous injection of Tra-IR700. The highest
signal was observed between Days 1 and 2 after Tra-
IR700 injection, and the signal gradually decreased
thereafter (Fig. 3a, b). As shown in Fig. 3c, the tumor-to-
background ratios increased over time in NCI-N87 tumors.
In contrast, upon visualization of the MKN-45 tumors
using IR700 fluorescence on Day 1 after injection of Tra-
IR700, the signals were significantly weaker than those of
the NCI-N87 tumors (n = 5 mice, P = 0.0024; Fig. 3b), and
the IR700 signal subsequently decreased. Except for the
HER2-positive tumors, no other IR700 localization was
found.
In vivo photoimmunochemotherapy for human gastric
cancer xenografts
The tumor xenografts reached 15 mm3 in volume approxi-
mately six days after subcutaneous injection of the NCI-
N87 cells, after which time the mice were subsequently
randomized into 8 groups. The NCI-N87 tumors were
irradiated with a single dose of NIR light on Day 1 after
Tra-IR700 injection, as the highest IR700 accumulation was
observed at that time point. As our previous studies and
preliminary results indicated that one-time injection of
300 μg antibody-IR700 conjugate followed by 100 J/cm2
NIR light irradiation was able to be achieved safely without
any significant side effects [12–14], this condition was
employed as the PIT treatment to assess the combination
treatment effects of PIT and 5-FU. As compared with the
various controls, apparent tumor growth inhibition was ob-
served upon treatment with Tra-IR700 injection followed
by NIR light irradiation after a few days. Importantly,
tumor growth was significantly suppressed in the PIT and
5-FU treatment group compared to the PIT alone group
(24 and 26 days after Tra-IR700 injection: P = 0.0415 and
P = 0.0414, respectively) (Fig. 4b). Pathological analysis re-
vealed cellular degeneration with nuclear swelling in the
tumor nodules treated with 5-FU alone; on the other
hand, massive granulation with inflammatory changes and
Fig. 2 In vitro photoimmunochemotherapy for human gastric cancer cells. a, b Human epidermal growth factor receptor 2 (HER2)-targeting
photoimmunotherapy (PIT) induced near-infrared (NIR) light dose-dependent cell death in NCI-N87 cells but not in MKN-45 cells. The percentage
of cell death was significantly increased by PIT treatment in combination with 5-fluorouracil (5-FU) compared to PIT alone. Significant cytotoxic
effects of 5-FU were observed in both NCI-N87 and MKN-45 cells. Spotted bar: no treatment, oblique line bar: trastuzumab-IR700 (Tra-IR700) (10 μg/ml)
alone, unfilled bar: Tra-IR700 (10 μg/ml) followed by NIR light irradiation (PIT alone), filled bar: addition of 5-FU (3 μM). Data are presented
as means ± SEM (n= 3, *P< 0.05, **P< 0.01, Student’s t test). c Significant long-term growth inhibition was observed in cells treated by PIT and 5-FU, as
determined by the trypan blue exclusion assay. Data are presented as means ± SEM (n = 3, *P < 0.05, ***P < 0.001 vs. treated with PIT
alone, Student’s t test). D While 5-FU and/or Tra-IR700 treatment induced an increase in caspase-3 activity, NIR light irradiation (PIT
treatment) did not further increase the caspase-3 activity in NCI-N87 cells. Data are presented as means ± SEM (n= 3, *P< 0.05, ***P < 0.001, Student’s t
test). Spotted bar: no treatment, oblique line bar: Tra-IR700 (10 μg/ml) alone, unfilled bar: Tra-IR700 (10 μg/ml) followed by NIR light irradiation (PIT
alone), filled bar: addition of 5-FU (3 μM)
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scant viable cells were observed in the tumor nodules
treated with PIT in combination with 5-FU (Fig. 4c).
Discussion
PIT is a highly selective cancer therapy, which is based
on a molecular-targeted mAb conjugated to the photo-
sensitizer IR700 and the use of NIR light. We have pre-
viously reported that HER2 target-specific cell death was
achieved with a single dose of Tra-IR700 administration
followed by NIR light irradiation. However, some cancer
cells survived after PIT, and recurrences eventually de-
veloped in our in vivo model [12, 13]. Generally, mAb
distribution is heterogeneous in most tumors, especially
in peripheral locations where the tumors receive good
blood supply [13, 20–22]. In addition, tumor heterogen-
eity is relatively common in human epithelial carcinomas,
including in gastric cancer [9, 16, 17]. Taken together, this
suggests that the antitumor effects of PIT alone on human
gastric cancer may be limited. To solve this problem, we
here examined whether the antitumor effect was
enhanced by combining PIT with chemotherapy, as com-
pared with PIT alone, in human gastric cancer cells. Our
findings suggest that PIT in combination with 5-FU
showed enhanced antitumor effects in HER2-expressing
human gastric cancer through different cytotoxic mecha-
nisms, both in vitro and in vivo.
Flow cytometric analyses revealed that the relative
MFI from the Tra-IR700 signal compared to the isotype
control was much higher in NCI-N87 cells, whereas
MKN-45 cells showed a very low relative MFI (Fig. 1a, b).
In both cell lines, complete signal blocking was induced
by adding excess unconjugated trastuzumab, indicating
Fig. 3 Human epidermal growth factor receptor 2 (HER2)-specific accumulation of trastuzumab-IR700 conjugate (Tra-IR700) in vivo. a Tra-IR700
distribution over time was assessed using an in vivo imaging system. NCI-N87 tumors (right dorsum) were clearly and selectively visualized by
IR700 fluorescence as early as 1 day after Tra-IR700 injection. Conversely, MKN-45 tumors (left dorsum) were only weakly visualized by
IR700 fluorescence, and the signals gradually attenuated over time (n = 5 mice). b Fluorescence intensity of IR700 in NCI-N87 tumors,
MKN-45 tumors, and background. Data are presented as means ± SEM (n= 5 mice, ** P< 0.01 vs. MKN-45 tumors, Student’s t test). c Tumor-to-background
ratios of IR700 fluorescence intensity in NCI-N87 and MKN-45 tumors. Data are presented as means ± SEM (n= 5 mice, ** P< 0.01, *** P< 0.001 vs. MKN-45
tumors, Student’s t test)
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that the cellular membrane binding of Tra-IR700 was
HER2-specific. Moreover, fluorescence microscopy clearly
detected IR700 fluorescence after incubation with Tra-
IR700 for 3 h in NCI-N87 cells, but not in MKN-45 cells.
Thus, as the HER2 expression in MKN-45 cells was deter-
mined to be very weak, we considered MKN-45 cells as a
HER2-negative control in this study. Consistent with pre-
vious reports, necrotic cell death was rapidly induced in
NCI-N87 cells treated with Tra-IR700 upon NIR light ir-
radiation, as demonstrated by bleb formation and cellular
swelling. On the other hand, MKN-45 cells did not show
any morphological changes (Fig. 1c, e), indicating that
target-specific membrane binding of Tra-IR700 was re-
quired to induce phototoxicity.
Significant cytotoxicity due to treatment with the IC50
of 5-FU was observed in the LIVE/DEAD assay in both
NCI-N87 and MKN-45 cells, supporting the hypothesis
that 5-FU induces cell membrane damage by inhibiting
DNA synthesis during apoptosis [23, 24] (Fig. 2a, b). In
contrast, we observed significant cytotoxicity treated
with Tra-IR700 compared to the untreated controls only
in NCI-N87 cells, and there was no significant differ-
ences in the percentage of cell death between treated
with Tra-IR700 and treated with unconjugated trastuzu-
mab (Additional file 1: Figure S1). These results suggested
that Tra-IR700 retained the same immunoreactivity as
native unconjugated trastuzumab for NCI-N87 cells.
There was a significant increase in caspase-3 activity when
NCI-N87 cells were treated with 5-FU and/or Tra-IR700
without NIR light, however, NIR light irradiation after
incubation with Tra-IR700 or Tra-IR700 in combination
with 5-FU did not result in any additional increases in
caspase-3 activity not only just after NIR light irradiation
but also 24 h after the irradiation (Additional file 1:
Figure S2). These results indicate that 5-FU and/or
Tra-IR700 treatment induces apoptosis, while PIT
treatment (NIR light with Tra-IR700) does not in-
duce additional apoptosis. Taken together with these
Fig. 4 In vivo photoimmunochemotherapy for human gastric cancer xenografts. a Experimental protocol of photoimmunochemotherapy in vivo.
(a) No treatment, (b) 30 μg/g/day of 5-fluorouracil (5-FU) i.p. without near-infrared (NIR) light irradiation, (c) 300 μg of trastuzumab-IR700 conjugate
(Tra-IR700) i.v. without NIR light irradiation, (d) NIR light irradiation (100 J/cm2) without 5-FU or Tra-IR700 injection, (e) 30 μg/g/day of 5-FU i.p. and
300 μg of Tra-IR700 i.v. without NIR light irradiation, (f) 30 μg/g/day of 5-FU i.p. followed by NIR light irradiation (100 J/cm2), (g) 300 μg of Tra-IR700 i.v.
followed by NIR light irradiation (100 J/cm2), and (h) 30 μg/g/day of 5-FU i.p. and 300 μg of Tra-IR700 i.v. followed by NIR light irradiation (100 J/cm2).
Tra-IR700 injection was performed at the time of mouse randomization (Day 0), and NIR light irradiation was performed 24 h after Tra-IR700 injection
(Day 1). Injection of 5-FU was performed on 3 consecutive days (Day 1 [just after NIR light irradiation], Day 2, and Day 3; total amount, 90 μg/g). Open
downwards arrow: 300 μg of Tra-IR700 i.v.; filled upwards arrow: 30 μg/g of 5-FU i.p. b Photoimmunochemotherapy resulted in marked antitumor effects
compared to photoimmunotherapy (PIT) alone. A significant therapeutic effect was observed in mice treated with PIT in combination with 5-FU compared
to in mice treated with PIT alone on Days 24 and 26 after the initial treatment. Data are presented as means ± SEM (at least n= 10 mice in each group,
* P< 0.05 vs. treated with PIT alone, Mann–Whitney U test). c Histological observations of the negative control and treated NCI-N87 tumors (n= 3 mice,
hematoxylin and eosin staining). Bleeding and massive granulation with inflammatory changes were observed, and only scant viable cells were present in
the tumor nodules treated with PIT in combination with 5-FU. Scale bar, 100 μm
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results, rapid necrotic cell death in response to NIR
light (with Tra-IR700) in addition to apoptotic cell
death in response to 5-FU and Tra-IR700 treatment
play major roles in this combination treatment.
Additionally, long-term cytotoxicity was assessed by
the trypan blue exclusion assay, which confirmed the en-
hanced treatment effect of PIT and 5-FU combination
treatment in NCI-N87 cells (Fig. 2c).
The in vivo biodistribution study by detecting IR700
fluorescence revealed that HER2-positive NCI-N87 tu-
mors specifically showed IR700 fluorescence starting at
Day 1 after intravenous injection of Tra-IR700, and this
signal continued to increase until Day 2 after injection.
In these tumors, the tumor-to-background ratio was in-
creased over time, likely owing to differences in the
clearance between the antibody-specific binding and
nonspecific blood pool. In contrast, IR700 fluorescence
in HER2-negative MKN-45 tumors, as well as in the
background normal tissues, was observed for up to
1 day after injection, and thereafter gradually decreased.
These findings suggest that HER2-specific IR700 fluores-
cence persists through specific membrane binding with
trastuzumab, whereas IR700 fluorescence from nonspe-
cific tumor vessel volume and/or blood pools is distrib-
uted similar to in normal tissues (Fig. 3a, b); based on
these findings, we irradiated NIR light for IR700-
localizing tumors on Day 1 after Tra-IR700 injection.
Finally, as mentioned above, our previous studies dem-
onstrated that one-time PIT treatment (i.e. mAb-IR700
injection followed by NIR light irradiation) significantly
induced target-specific tumor cell death; however, tumor
recurrences were eventually seen [12, 14]. Consistent
with these previous studies, in the present study, one-
time PIT treatment for NCI-N87 tumors with Tra-IR700
was found to significantly suppress tumor growth com-
pared to in the non-treatment control. Furthermore,
when 5-FU treatment was added to the PIT treatment,
significant tumor growth inhibition compared to PIT
treatment alone was observed even in the long-term, in-
dicating a synergistic treatment effect of photoimmuno-
chemotherapy. This combined treatment effect can be
explained by the different mechanisms of tumor cell
death induced by PIT and 5-FU. The results of our pre-
vious studies showed that PIT mainly induces rapid
necrotic cell death in response to NIR light irradiation
[12–14], whereas 5-FU, as well as trastuzumab, induces
apoptotic cell death [23, 24]. Accordingly, whereas only
subtle apoptotic changes were observed in the tumors
treated with 5-FU alone, pathological analysis showed
massive necrotic damage and scant tumor cells with
nuclear swelling in the tumors treated with PIT and 5-
FU (Fig. 4c).
There are some limitations associated with this
method. In clinical cases, the efficacy of Tra-IR700
mediated PIT is limited to gastric cancers because over-
expression of HER2 only account for approximately
20 % of all gastric cancer patients [9, 10], however, this
study suggests that the Tra-IR700 mediated PIT and PIT
in combination with 5-FU could become effective ther-
apies for HER2-positive cases. Furthermore, because of
the inhomogeneity of antibody microdistribution in the
tumors, NIR light might not be effective for eradicating
whole tumor cells, even if those cells express the target
molecule abundantly. In addition, the effects of mAb
monotherapy on epithelial cancers, such as gastric
cancer, are somewhat limited, owing to molecular
heterogeneity, and small molecule chemotherapeutic
compounds should be considered to improve the antitu-
mor effects in these cases. Furthermore, IR700 is
relatively hydrophilic compared to the traditional photo-
sensitizers used for photodynamic therapy, and PIT is
considered more effective and less harmful than conven-
tional therapies, mainly owing to the fact that the mAb-
IR700 pharmacokinetics allow better specific tumor up-
take of IR700 and longer wavelength excitation, thereby
allowing better tissue penetration [25–28]. Nevertheless,
the limited depth of penetration of NIR light is the pri-
mary limitation of this method for clinical gastric can-
cers. Endoscopic NIR light irradiation could achieve
sufficient tissue penetration and improve local tumor
control for localized lesions of gastric neoplastic mucosa.
In addition, laparoscopic NIR irradiation could improve
clinical applicability for disseminated peritoneal gastric
cancer and it is further supported by a previous study
that demonstrated Tra-IR700 mediated PIT induced sig-
nificant HER2-targeted tumor killing effect in a mouse
model of disseminated peritoneal gastric cancer [29].
However, although the light power is reduced with increas-
ing depth from the light source as a result of light scattering
and absorption by the tissues, utilizing a chemotherapeutic
agent, such as 5-FU in this case, may still allow tumor cell
killing in the deeper tissues where the light is not strong
enough to activate the photosensitizer.
Conclusions
We here found that treatment with PIT in combination
with 5-FU resulted in an enhanced antitumor effect
through different mechanisms of tumor cell death, as
compared to PIT monotherapy, for HER2-expressing
human gastric cancer in vitro and in vivo. Immediate
target-specific necrotic cell death was induced with one-
time administration of Tra-IR700 followed by NIR light
irradiation, as determined by HER2-specific IR700 fluor-
escence imaging, and subsequent 5-FU administration
was found to enhance this antitumor effect, thereby
effectively inhibiting tumor recurrence. Taken together,
our results suggest that photoimmunochemotherapy
represents a promising method for treating human
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gastric cancer, and further studies should be conducted
to evaluate whether these results translate into the
clinical setting.
Additional file
Additional file 1: Figure S1. LIVE/DEAD assay. Figure S2. Caspase-3
activity assay. (DOCX 397 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KI conducted the experiments, performed the analyses, and wrote the
manuscript; M Mitsunaga planned the project, designed and conducted
the experiments, wrote the manuscript, and supervised the project; SA,
MS, M Matsuoka, HK and HT wrote the manuscript and supervised the
project. All authors have read and approved the final manuscript.
Acknowledgements
We thank Yuko Kamata for providing technical support and Dr. Toru Harada
for tissue processing. Grant supports: Grant-in-Aid for Young Scientists (A)
(JSPS KAKENHI 26710010 to M.Mitsunaga), Uehara Memorial Foundation to
M. Mitsunaga, Kato Memorial Bioscience Foundation to M. Mitsunaga,
Mochida Memorial Foundation for Medical and Pharmaceutical Research to
M. Mitsunaga, Takeda Science Foundation to M. Mitsunaga, Kowa Life
Science Foundation to M. Mitsunaga, Nakayama Cancer Research
Institute to M. Mitsunaga, and The Jikei University Research Fund to
K.I. and M. Mitsunaga.
Author details
1Division of Gastroenterology and Hepatology, Department of Internal
Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi,
Minato, Tokyo 105-8461, Japan. 2Molecular Imaging Program, Center for
Cancer Research, National Cancer Institute, NIH, Building 10, RoomB3B69,
MSC1088, Bethesda, MD 20892-1088, USA.
Received: 28 July 2015 Accepted: 19 January 2016
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A,
et al. Survival after gastric adenocarcinoma resection: eighteen-year
experience at a single institution. J Gastrointest Surg. 2005;9:718–25.
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
4. Waldmann TA. Immunotherapy: past, present and future. Nat Med.
2003;9:269–77.
5. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of
cancer. Nat Rev Cancer. 2006;6:559–65.
6. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody
successes in the clinic. Nat Biotechnol. 2005;23:1073–8.
7. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a
novel therapeutic target. Ann Oncol. 2008;19:1523–9.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev
Mol Cell Biol. 2001;2:127–37.
9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.
Trastuzumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2-positive advanced gastric or gastro-
oesophageal junction cancer (ToGA): a phase 3, open-label, randomized
controlled trial. Lancet. 2010;376:687–97.
10. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison
of HER2 gene amplification assessed by fluorescence in situ hybridization and
HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Oncol Rep. 2006;15:65–71.
11. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y.
Antitumor activity of trastuzumab in combination with chemotherapy in
human gastric cancer xenograft models. Cancer Chemother Pharmacol.
2007;59:795–805.
12. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H.
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting
specific membrane molecules. Nat Med. 2011;17:1685–91.
13. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared
theranostic photoimmunotherapy (PIT): repeated exposure of light
enhances the effect of immunoconjugate. Bioconjug Chem. 2012;23:604–9.
14. Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H.
Immediate in vivo target-specific cancer cell death after near infrared
photoimmunotherapy. BMC Cancer. 2012;12:345.
15. Weiner LM, Surana R, Wang S, Monoclonal antibodies. Versatile platforms for
cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27.
16. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al.
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase
IIα gene amplification, intestinal type, poor prognosis and sensitivity to
trastuzumab. Ann Oncol. 2005;16:273–8.
17. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al.
Assessment of a HER2 scoring system for gastric cancer: results from a
validation study. Histopathology. 2008;52:797–805.
18. Macdonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer:
present status, future prospects. Semin Oncol. 1988;15:42–9.
19. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in
athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148–54.
20. Kosaka N, Ogawa M, Paik DS, Paik CH, Choyke PL, Kobayashi H.
Microdistribution of fluorescently-labeled monoclonal antibody in a
peritoneal dissemination model of ovarian cancer. Proc SPIE. 2010;7576:
7576041–9.
21. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for
cancer. Annu Rev Med. 2003;54:343–69.
22. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of
monoclonal antibodies and other macromolecules in tumors: significance of
elevated interstitial pressure. Cancer Res. 1988;48:7022–32.
23. Danenberg PV, Langenbach RJ, Heidelberger C. Structure of reversible and
irreversible complexes of thymidylate synthetase and fluorinated pyrimidine
nucleotides. Biochemistry. 1974;13:926–33.
24. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate
synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974;13:471–81.
25. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of
animal tumors with tumor-specific monoclonal antibody-hematoporphyrin
conjugates. J Immonol. 1983;130:1473–7.
26. Wilson BC, Patterson MS. The determination of light fluence distributions for
photodynamic therapy. In: Kessel D, editor. Photodynamic therapy of
neoplastic disease, vol. 1. Boca Raton: CRC press; 1990. p. 129–44.
27. Sobolev AS, Jans DA, Rosenkranz AA. Targeted intracellular delivery of
photosensitizers. Prog Biophys Mol Biol. 2000;73:51–90.
28. Carcenac M, Dorvillius M, Garambois V, Glaussel F, Larroque C, Langlois R,
et al. Internalisation enhances photo-induced cytotoxicity of monoclonal
antibody-phthalocyanine conjugates. Br J Cancer. 2001;85:1787–93.
29. Sato K, Choyke PL, Kobayashi H. Photoimmunotherapy of gastric cancer
peritoneal carcinomatosis in a mouse model. PLoS One. 2014;9(11):e113276.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ito et al. BMC Cancer  (2016) 16:37 Page 10 of 10
